Cytokine variations in patients with hormone treated prostate cancer

Journal of Urology

Volumn 164, Issue 3 I, 2000, Pages 722-725

  Wise, Gilbert J ^a   Marella, Venkata K ^a   Talluri, Giridhar ^a   Shirazian, Djamshid ^a  

^a MAIMONIDES MEDICAL CENTER   (United States)

Author keywords

Cytokines; Prostate; Prostatic hyperplasia; Prostatic neoplasms

Indexed keywords

CYTOKINE; GONADORELIN; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; HORMONAL THERAPY; HORMONE SENSITIVITY; HUMAN; IMMUNE RESPONSE; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY;

EID: 0033883914     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0022-5347(05)67289-8     Document Type: Article

References (17)

1. Landis, S. H., Murray, T., Bolden, S. et al: Cancer statistics, 1998. CA Cancer J Clin, 48: 6, 1998
2. Parker, S. L., Tong, T., Bolden, S. et al: Cancer statistics, 1996. CA Cancer J Clin, 46: 5, 1996
3. Sokoloff, M. H., Tso, C.-L., Kaboo, R. et al: In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines. Cancer, 77: 1862, 1996
4. Huggins, C. and Hodges, C. V.: The effect of castration, of estrogen, and of androgen injection on serum phosphatases, in metastatic carcinoma of the prostate. Cancer Res, 1: 293, 1941
5. Nupponen, N. N., Kakkola, L., Koivisto, P. et al: Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol, 153: 141, 1998
6. Trapman, J. and Cleutjens, K. B.: Androgen-regulated gene expression in prostate cancer. Semin Cancer Biol, 8: 29, 1997
7. Lee, C.: Cellular interactions in prostate cancer. Br J Urol, suppl., 79: 21, 1997
8. Isaacs, J. T.: The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am, 26: 263, 1999
9. Scott, P., Pearce, E., Cheever, A. W. et al: Role of cytokines and CD4+ T-cell subsets in the regulation of parasite immunity and disease. Immunol Rev, 112: 161, 1989
10. Mokhtarian, F., Shi, Y., Shirazian, D. J. et al: Defective production of anti-inflammatory cytokine, TGF-β by T cell lines of patients with active multiple sclerosis. J Immunol, 152: 6003, 1994
11. Durum, S. K. and Oppenheim, J. J.: Proinflammatory cytokines and immunity. In: Fundamental Immunology, 3rd ed. Edited by W. E. Paul. New York: Raven Press, 1993
12. Lucey, D. R.: Evolution of the type-1 (Thl)-type-2 (Th2) cytokine paradigm. Infect Dis North Am, 13: 1, 1999
13. Mossman, T. R. and Coffman, R. L.: Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional peptides. Ann Rev Immunol, 7: 145, 1989
14. Diaz, M., Abdul. M. and Hoosein, N.: Modulation of neuroendocrine differentiation in prostate cancer by interleukin-1 and -2. Prostate, suppl., 8: 32, 1998
15. Wang, M., Fudge, K., Rhim, J. S. et al: Cytokine regulation of the matrix metalloproteinases and their inhibitors in human papillomavirus-18 transformed human prostatic tumor cell lines. Oncol Res, 8: 303, 1996
16. Levesque, E., Beaulieu, M., Guillemette, C. et al: Effect of interleukins on UGT2B15 and UGT2B17 steroid uridine diphosphate-glucuronosyltransferase expression and activity in the LNCaP cell line. Endocrinology, 139: 2375, 1998
17. Akimoto, S., Okumura, A. and Fuse, H.: Relationship between serum levels of interleukin-6, tumor necrosis factor-alpha and bone turnover markers in prostate cancer patients. Endocr J, 45: 183, 1998